KR910000138A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR910000138A
KR910000138A KR1019890007835A KR890007835A KR910000138A KR 910000138 A KR910000138 A KR 910000138A KR 1019890007835 A KR1019890007835 A KR 1019890007835A KR 890007835 A KR890007835 A KR 890007835A KR 910000138 A KR910000138 A KR 910000138A
Authority
KR
South Korea
Prior art keywords
ibuprofen
salt
cyclodextrin
magnesium
solution
Prior art date
Application number
KR1019890007835A
Other languages
English (en)
Inventor
헌터 크리스토퍼
야유 데이비드
Original Assignee
피터 로스 밀리간
레키트 앤드 콜맨 프로덕트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 로스 밀리간, 레키트 앤드 콜맨 프로덕트 리미티드 filed Critical 피터 로스 밀리간
Publication of KR910000138A publication Critical patent/KR910000138A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

내용 없음

Description

약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. β-사이크로덱스트린과 나트륨, 칼륨, 암모늄, 마그네슘, 칼슘, 아르기닌, 글리신 또는 리신 염중에서 선택된 이부프로펜 염의 복합체(여기서 이부프로펜 대β-사이클로릭덱스트린의 몰비는 1:0.20 내지 1:0.75이다).
  2. 제1항에 있어서, 이부프로펜 나트륨 염과의 복합체.
  3. 이부프로펜, β-사이클롤덱스트린 및 물의 혼합물을 50 내지 80℃, 바람직하게는 약 70℃에서 혼합한 후, 생성된 분산액을 수산화나트륨 수용액으로 중화시켜 투명 용액을 형성시킨 다음, 30 내지 40℃로 냉각시킨 후 상기 용액을 분무 입제화, 분무 건조, 드럼 건조 또는 냉동 건조와 같은 방법으로 건조시켜 수분을 제거함을 특징으로 하여, 제2항에 따르는 복합체를 제조하는 방법.
  4. 제3항에 있어서, 건조 방법이 분무 건조이고, 분무 건조시키기 전의 용액의 농도가 바람직하게는 5 내지 40%(W/W), 가장 바람직하게는 약 35%(W/W)인 방법.
  5. 제4항에 있어서, 건조 방법이 주 유입구의 온도가 170 내지 200℃, 바람직하게는 약 195℃이고, 유동 베드 유입구(fluid bed inlet)의 온도가 90 내지 110℃, 바람직하게는 약 100℃이며, 배출구의 온도가 약 76℃이고 총공기 건조량이 620㎏/시간인 유동 베드 분무건조법(fluid bed spray drying)인 방법.
  6. 제3항 내지 5항중 어느 한 항에 있어서, 수분을 제거하기 전에 β-사이클로덱스트린 이부프로펜 나트륨염 복합체의 용액에 폴리비닐 피롤리딘, 폴리에틸렌 글리콜, 카복시 비닐 폴리메틸렌 또는 이의 혼합물과 같은 수용성 결합제는 가하는 방법.
  7. 제6항에 있어서, 복합체 중량에 대한 수용성 결합제의중량이 0.1 내지 5%, 바람직하게는 3 내지 4%인 방법.
  8. 이부프로펜 염이 칼륨, 암모늄, 아르기닌, 글리신 또는 리신 염중에서 선택되고 제3항 내지 7항중 어느 한항에 따라서 나트륨 염에 대해 사용하는 방법과 유사한 방법으로 중화 단계에서 수산화칼륨, 탄산칼륨, 수산화암모늄, 아르기닌, 글리신 또는 리신을 사용하여, 제1항에 따르는 복합체를 제조하는 방법.
  9. 이부프로펜 염이 마그네슘, 또는 염중에서 선택되고 나트륨 염 복합체의 수용액을 염화 칼슘 염화 마그네슘, 황산칼슘, 마그네슘, 칼슘 글루코네이트, 마그네슘 글루코네이트 또는 칼슘 락테이트와 같은 적합한 칼슘 또는 마그네슘 염과 혼합하여, 제1항에 따르는 복합체를 제조하는 방법.
  10. 제1항 또는 제2항에 따르는 β-사이클로덱스트린/이부프로펜 염 복합체를 약제학적으로 허용되는 희석제 또는 담체와 함께 함유하는 경구투여용 약제학적 조성물.
  11. 제10항에 있어서, 조성물을 물에 가할 때 생성된 용액의 pH가 6.0 내지 8.0이 되도록 하는 양의 약제학적으로 허용되는 산 염(예:나트륨 시트레이트)또는 완충 시스템을 포함하는 산제, 입제 또는 정제형인 조성물.
  12. 제10항 또는 11항에 있어서, 이부프로펜을 50 내지 600㎎ 바람직하게는 200 내지 400㎎씩 등량으로 함유하는 단위 투여형인 조성물.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007835A 1988-06-09 1989-06-08 약제학적 조성물 KR910000138A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8813682.5 1988-06-09
GB888813682A GB8813682D0 (en) 1988-06-09 1988-06-09 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR910000138A true KR910000138A (ko) 1991-01-29

Family

ID=10638367

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007835A KR910000138A (ko) 1988-06-09 1989-06-08 약제학적 조성물

Country Status (18)

Country Link
US (1) US5019563A (ko)
EP (1) EP0346006B1 (ko)
JP (1) JPH02243649A (ko)
KR (1) KR910000138A (ko)
AT (1) ATE83924T1 (ko)
AU (1) AU609988B2 (ko)
CA (1) CA1320192C (ko)
DE (1) DE68904121T2 (ko)
DK (1) DK280789A (ko)
ES (1) ES2052914T3 (ko)
FI (1) FI93692C (ko)
GB (2) GB8813682D0 (ko)
GR (1) GR3006729T3 (ko)
IE (1) IE61616B1 (ko)
NO (1) NO175039B (ko)
NZ (1) NZ229204A (ko)
PT (1) PT90760B (ko)
ZA (1) ZA893913B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100730393B1 (ko) * 2005-06-10 2007-06-20 한국콜마 주식회사 이부프로펜 및 아르기닌을 함유하는 약학 조성물의제조방법

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
DE3922441A1 (de) * 1989-07-07 1991-01-17 Pharmatrans Sanaq Ag Ibuprofen- und s-(+)-ibuprofen-zubereitungen und verfahren zu ihrer herstellung
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
ES2093192T3 (es) * 1991-03-22 1996-12-16 Merck & Co Inc Formulacion farmaceutica con elevado contenido de lisinato de ibuprofeno.
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
US5321014A (en) * 1991-06-28 1994-06-14 The United States Of America As Represented By The Department Of Health And Human Services Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells
IT1255007B (it) * 1991-07-01 1995-10-11 Altergon Sa Sale solubile dell'ibuprofen c0n n-(2-idrossietil) pirrolidina e composizioni farmaceutiche che li contengono.
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
HU210922B (en) * 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
CN1088600C (zh) * 1993-07-31 2002-08-07 史密丝克莱恩比彻姆有限公司 布洛芬－β－环糊精配合物的用途
US5582351A (en) * 1993-08-09 1996-12-10 Tsau; Josef Convenient to use aspartame and method of making
GB9316580D0 (en) * 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
CA2190598A1 (en) * 1994-05-27 1995-12-07 Lawrence John Penkler Pharmaceutical composition
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
IT1301966B1 (it) 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US6727286B2 (en) 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US20060233873A1 (en) * 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
AU2004320488A1 (en) * 2004-06-07 2005-12-22 Strides Arcolab Limited Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
GB2423710A (en) * 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
CN103622926A (zh) * 2005-11-02 2014-03-12 帝国制药美国公司 感官上可接受的布洛芬口服给药制剂、制备和使用它的方法
MX2008011823A (es) * 2006-03-16 2008-10-31 Novartis Ag Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
WO2011001228A1 (en) * 2008-08-14 2011-01-06 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN102448499A (zh) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 赖氨酸布洛芬口服混悬剂
PL2253329T3 (pl) * 2009-04-27 2017-08-31 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Zawiesina doustna soli lizynowej ibuprofenu
ES2347754B8 (es) * 2009-04-27 2012-06-04 Laboratorio De Aplicaciones Farmacodinamicas, S.A Suspension oral de lisinato de ibuprofeno
HUE037827T2 (hu) * 2009-06-22 2018-09-28 Wyeth Llc Nátrium-ibuprofen tabletták és eljárások nátrium-ibuprofent tartalmazó gyógyszerészeti készítmények elõállítására
CN101978955A (zh) * 2010-11-05 2011-02-23 航天中心医院 右旋布洛芬氨基酸盐片剂及其制备方法
US10098964B2 (en) 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5646837A (en) * 1979-09-27 1981-04-28 Kowa Yakuhin Kogyo Kk Preparation of ibuprofen clathrate compound
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100730393B1 (ko) * 2005-06-10 2007-06-20 한국콜마 주식회사 이부프로펜 및 아르기닌을 함유하는 약학 조성물의제조방법

Also Published As

Publication number Publication date
DE68904121D1 (de) 1993-02-11
FI93692B (fi) 1995-02-15
GB2219585B (en) 1991-11-06
FI93692C (fi) 1995-05-26
GB8813682D0 (en) 1988-07-13
CA1320192C (en) 1993-07-13
NO892340L (no) 1989-12-11
DK280789D0 (da) 1989-06-08
ATE83924T1 (de) 1993-01-15
DK280789A (da) 1989-12-12
ES2052914T3 (es) 1994-07-16
NO175039C (ko) 1994-08-24
PT90760A (pt) 1989-12-29
AU609988B2 (en) 1991-05-09
AU3492789A (en) 1989-12-14
FI892780A (fi) 1989-12-10
IE891757L (en) 1989-12-09
FI892780A0 (fi) 1989-06-07
JPH02243649A (ja) 1990-09-27
ZA893913B (en) 1990-02-28
GB2219585A (en) 1989-12-13
NZ229204A (en) 1992-03-26
NO892340D0 (no) 1989-06-07
US5019563A (en) 1991-05-28
DE68904121T2 (de) 1993-05-06
PT90760B (pt) 1994-10-31
NO175039B (no) 1994-05-16
EP0346006A1 (en) 1989-12-13
GB8911938D0 (en) 1989-07-12
GR3006729T3 (ko) 1993-06-30
IE61616B1 (en) 1994-11-16
EP0346006B1 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
KR910000138A (ko) 약제학적 조성물
CA1040532A (en) Process for producing solid bismuth-containing pharmaceutical compositions
AU594265B2 (en) Therapeutic compositions
CA1295611C (en) Association complex comprising pullulan and polyethylene glycol, and preparation and uses of the same
US4956386A (en) Pharmaceutical compositions and process for their preparation
HU195617B (en) Process for producing pharmaceutical compositions containing 2-/4-isobutyl-phenyl6-propionic acid
JP2907299B2 (ja) 胃酸を結合する薬学的製剤
US5244881A (en) Compositions based on imipyramine
US4409233A (en) Highly concentrated preparations of dopa compounds
GR3018970T3 (en) Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions.
DE69304195D1 (de) Salzprodukt und verfahren zur dessen herstellung
ES8102804A1 (es) Un metodo para preparar compuestos utiles como precursores de aminoacidos esenciales y semiesenciales
JPS5978116A (ja) スクラルフェ−ト製剤
JPH0437068B2 (ko)
MY117606A (en) Orally administrable formulations of quinolone- or naphthyridonecarboxylic acids
IE873006L (en) Salt of diclofenac with a cyclic organic base and¹pharmaceutical compositions which contain it
JP2004067682A (ja) 抗生物質活性を有する薬学的組成物
JP2891744B2 (ja) パントテン酸カルシウム組成物およびその製造方法
CA2187442A1 (en) Solid Compositions Containing Amine Oxide-Maleic Acid Salts
IL103005A0 (en) Process for producing pharmaceutical compositions
JPS5781409A (en) External plaster
CA1070299A (en) Stabilized solid form choline salicylate compositions
JPS58101660A (ja) ステビオ−ルバイオサイドの溶解性改善法
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt
JPH04312530A (ja) 自由流動性の直接圧縮可能なビタミンの製造方法

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E601 Decision to refuse application